Related Experiment Video
Updated: Oct 3, 2025
Synthetic Methodology for Asymmetric Ferrocene Derived Bio-conjugate Systems via Solid Phase Resin-based Methodology
Published on: March 12, 2015
Novel ferrocenylbisphosphonate hybrid compounds: Synthesis, characterization and potent activity against cancer cell
Chioma G Anusionwu1, Blessing A Aderibigbe2, Samson A Adeyemi3
1Department of Chemical Sciences, University of Johannesburg, Doornfontein Campus, Johannesburg, South Africa.
Abstract:
The toxicity of existing anticancer agents on healthy cells and the emergence of multidrug-resistance cancer cells have led to the search for less toxic anticancer agents with different mechanisms of action. In this study, a novel class of ferrocenylbisphosphonate hybrid compounds (H1-H8) were designed and characterized using NMR, IR and HRMS. The in vitro anticancer activity of the hybrid compounds on HeLa (cervix adenocarcinoma) and A549 (non-small cell lung cancer cell lines) was evaluated. The structure-activity relationship of the hybrid molecules was also studied. The lead compound, tetraethyl (3-(4-oxo-4-ferrocenylbutanamido) propane-1-1-diylbis(phosphonate) (H6) exhibited higher cytotoxicity on A549 (IC50 = 28.15 µM) than cisplatin (IC50 = 58.28 µM), while its activity on HeLa cells (IC50 = 14.69 µM) was equivalent to that of cisplatin 15.10 µM (HeLa cells). H6 (IC50 = 95.58 µM) was also five times less toxic than cisplatin (IC50 = 20.86 µM) on fibroblast NIH3T3 suggesting that H6 can be a future replacement for cisplatin due to its non-toxicity to healthy cells. Interestingly, some ferrocene and bisphosphonate parent compounds exhibited promising anticancer activity with 4-ferrocenyl-4-oxobutanoic acid (FI) exhibiting higher cytotoxic activity (IC50 = 1.73 µM) than paclitaxel (IC50 = 3.5 µM) on A549 cell lines. F1 also exhibited lower cytotoxicity than paclitaxel and cisplatin on the normal murine fibroblast cell line (NIH3T3). The molecular docking studies showed H6 strong binding affinity for the STAT3 signaling pathway in A549 cell line, and the MAdCAM-1 and cellular tumor antigen p53 proteins in HeLa cell lines.
Insights
Novel ferrocenylbisphosphonate compounds show potent anticancer activity against A549 and HeLa cells with reduced toxicity to healthy cells. The lead compound H6 demonstrates potential as a safer alternative to cisplatin, offering a promising new direction in cancer therapy.
Area of Science:
- Medicinal Chemistry
- Organic Synthesis
- Pharmacology
Background:
- Existing anticancer agents face challenges due to toxicity to healthy cells and the rise of multidrug-resistant cancers.
- There is an ongoing need for novel anticancer drugs with improved efficacy and reduced side effects.
Purpose of the Study:
- To design, synthesize, and characterize novel ferrocenylbisphosphonate hybrid compounds.
- To evaluate the in vitro anticancer activity of these compounds against human cancer cell lines (HeLa and A549).
- To investigate the structure-activity relationship and potential of these compounds as less toxic anticancer agents.
Main Methods:
- Synthesis and characterization of ferrocenylbisphosphonate hybrid compounds (H1-H8) using NMR, IR, and HRMS.
- In vitro cytotoxicity evaluation against HeLa (cervix adenocarcinoma) and A549 (non-small cell lung cancer) cell lines.
- Comparative toxicity assessment on normal murine fibroblast NIH3T3 cells.
- Molecular docking studies to predict binding affinities with key biological targets.
Main Results:
- The lead compound H6 demonstrated significant cytotoxicity against A549 and HeLa cells, comparable or superior to cisplatin.
- H6 exhibited notably lower toxicity towards normal fibroblast NIH3T3 cells compared to cisplatin, indicating a favorable safety profile.
- The parent compound 4-ferrocenyl-4-oxobutanoic acid (F1) showed potent anticancer activity against A549 cells, outperforming paclitaxel.
- Molecular docking revealed strong binding of H6 to STAT3, MAdCAM-1, and p53 proteins, suggesting potential mechanisms of action.
Conclusions:
- Ferrocenylbisphosphonate hybrid compounds represent a promising class of anticancer agents with a potentially improved therapeutic index.
- The lead compound H6 shows significant potential as a next-generation anticancer drug due to its efficacy and reduced toxicity.
- Further investigation into the mechanisms of action and in vivo efficacy of these compounds is warranted.
